OTSUKA PHARMACEUTICAL CO., LTD.

iBio, Inc. reports FY2024 financial results, highlighting significant progress in AI-driven antibody immunotherapies, including collaborations, technology advancements, and financial improvements. Key developments include the launch of ShieldTx™, sale of PD-1 asset to Otsuka, and collaboration with AstralBio. The company strengthened its financial position through debt elimination, capital raises, and strategic transactions, reducing net loss to $24.9 million from $65 million in FY2023. iBio holds $14.4 million in cash and equivalents as of June 30, 2024.